(Q37142138)

18 August 2017

1 reference

title

Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update (English)

1 reference

18 August 2017

main subject

cardiovascular disease

1 reference

Pantelis A Sarafidis

1

1 reference

18 August 2017

publication date

15 April 2008

1 reference

Fundamental and Clinical Pharmacology

18 August 2017

published in

1 reference

18 August 2017

volume

22

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

247-264

1 reference

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Standards of medical care in diabetes--2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones: a new class of antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Insulin resistance and its treatment by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Antihypertensive agents, insulin sensitivity, and new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The metabolic syndrome: a glance at its history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The natural history of type 2 diabetes. Implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Addressing the insulin resistance syndrome: a role for the thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The effects of thiazolidinediones on blood pressure levels - a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A meta-analysis of the effect of thiazolidinediones on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones and diabetic nephropathy: need for a closer examination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone Lowers Blood Pressure and Increases Arterial Compliance in Postmenopausal Women With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Non-alcoholic fatty liver disease in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Non-alcoholic fatty liver disease: further expression of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Insulin resistance in polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones for treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effects of thiazolidinediones on differentiation, proliferation, and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Hepatotoxicity with thiazolidinediones: is it a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Troglitazone and liver injury: in search of answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Differentiating members of the thiazolidinedione class: a focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Type 2 diabetes, cardiovascular risk, and the link to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Thiazolidinediones for initial treatment of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Commentary: the PROactive study--the glass is half full

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Rosiglitazone and cardiovascular risk: weighing recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1472-8206.2008.00568.X

10.1111/J.1472-8206.2008.00568.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference